argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Real-time Euronext Bruxelles Other stock markets 04:15:13 20/05/2024 pm IST			5-day change	1st Jan Change
334.3 ^EUR	-1.65%		-2.31%	-2.68%

17/05	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	MT
15/05	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	MT

Argenx : argenx Reports First Quarter 2024 Financial Results and Provides Business Update

May 09, 2024 at 09:04 pm IST

argenx SE

argenx SE

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

Registration date09 may 2024 - 07:13

Statutory nameargenx SE

Titleargenx Reports First Quarter 2024 Financial Results and Provides Business Update

Previous result

Next result

Related downloads

202405090000000001_argenx Reports First Quarter 2024 Financial Results and Provides Business Update.pdf(opens in a new window)

Date last update: 09 May 2024

Attachments

Original Link
Permalink

Disclaimer

arGEN-X SE published this content on 09 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 May 2024 15:33:06 UTC.

Latest news about argenx SE

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	17/05	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	15/05	MT
Transcript : Argenx SE Presents at Bank of America Health Care Conference 2024, May-14-2024 10:00 AM	14/05
JPMorgan Cuts Price Target on Argenx to $500 From $560, Maintains Overweight Rating	13/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	10/05	MT
Indexes already back on top	10/05
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	09/05	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Fading Rate Cut Hopes	09/05	MT
Transcript : Argenx SE, Q1 2024 Earnings Call, May 09, 2024	09/05
Europe's STOXX 600 pauses after recent rally; BBVA weighs on Spain	09/05	RE
Argenx Q1 Loss Widens, Total Operating Income Rises	09/05	MT
U.S. Futures Edge Lower, European Stocks Mixed	09/05	DJ
European shares pause after recent rally, BoE decision in focus	09/05	RE
Argenx SE Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors	08/05	CI
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	03/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	17/04	MT
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	16/04	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	04/04	MT
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease	27/03	CI
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating	26/03	MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia	26/03	MT
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia	26/03	CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	21/03	MT
US Futures, European Stocks Rise After Fed Maintains Outlook	21/03	DJ

Chart argenx SE

Duration

Period

More charts

Company Profile

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.

Sector

Biotechnology & Medical Research

Calendar

25/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , BEL-20

More about the company

Income Statement Evolution

More financial data

Ratings for argenx SE

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

339.9 EUR

Average target price

432.9 EUR

Spread / Average Target

+27.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARGENX SE	-2.68%	2.2TCr
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.84%	11TCr
BIONTECH SE	-14.15%	2.19TCr
GENMAB A/S	-5.29%	1.92TCr
BEIGENE, LTD.	-4.16%	1.81TCr
WUXI APPTEC CO., LTD.	-38.29%	1.77TCr
NEUROCRINE BIOSCIENCES, INC.	+7.99%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+36.24%	1.24TCr
LEGEND BIOTECH CORPORATION	-24.95%	823.19Cr

Bio Therapeutic Drugs